Abstract
The presence of circulating anti-p53 antibodies (p53Ab) was investigated in 81 gastric cancer patients by ELISA. Preoperatively, anti-p53Ab were revealed in 13 cases (16%), including 3 early gastric cancers. No significant correlation of p53Ab with patient age, sex, pathological parameters and tumor markers, such as CEA and CA19-9 was observed, although p53Ab positivity tended to be associated with a higher rate of lymph node metastases (p = 0.073). We have found no significant correlation between p53Ab and poor survival rate (p = 0.325). In conclusion, we have observed that p53Ab are detectable in gastric cancer patients, even at early stages of disease, however, p53Ab have not served as a predictor of poor prognosis in gastric cancer in this series.
MeSH terms
-
Adenocarcinoma / blood*
-
Adenocarcinoma / immunology
-
Adenocarcinoma / mortality
-
Adenocarcinoma / surgery
-
Adult
-
Aged
-
Aged, 80 and over
-
Antibodies, Neoplasm / blood*
-
Biomarkers, Tumor / blood*
-
CA-19-9 Antigen / blood
-
Carcinoembryonic Antigen / blood
-
Disease Progression
-
Enzyme-Linked Immunosorbent Assay
-
Female
-
Gastrectomy
-
Humans
-
Lymphatic Metastasis
-
Male
-
Middle Aged
-
Neoplasm Proteins / immunology*
-
Neoplasm Staging
-
Preoperative Care
-
Prognosis
-
Stomach Neoplasms / blood*
-
Stomach Neoplasms / immunology
-
Stomach Neoplasms / mortality
-
Stomach Neoplasms / surgery
-
Survival Rate
-
Tumor Suppressor Protein p53 / immunology*
Substances
-
Antibodies, Neoplasm
-
Biomarkers, Tumor
-
CA-19-9 Antigen
-
Carcinoembryonic Antigen
-
Neoplasm Proteins
-
Tumor Suppressor Protein p53